Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis

Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DN...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardi, Maria R, Iannetta, Marco, Zingaropoli, Maria A, Salpini, Romina, Aragri, Marianna, Annecca, Rosanna, Pontecorvo, Simona, Altieri, Marta, Russo, Gianluca, Svicher, Valentina, Mastroianni, Claudio M, Vullo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
ID Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343960/
https://www.ncbi.nlm.nih.gov/pubmed/30697576
http://dx.doi.org/10.1093/ofid/ofy356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343960/
https://www.ncbi.nlm.nih.gov/pubmed/30697576
http://dx.doi.org/10.1093/ofid/ofy356

Ejemplares similares